After clinical trial rejection and no word on technology transfer, Olix rides a rollercoaster amid Peptron shock
Predicted impact: Low
Clinical trial rejection and unannounced technology transfer; vague, no size given, small relative to news flow.
OliX Pharmaceuticals올릭스
226950 · KOSDAQ · ₩226950 · 올릭스
₩90,600▼ ₩5,500 (5.72%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −9.13%
- Market cap
- ₩2.1T
- Enterprise value
- ₩1.9T
- P/E
- —
- P/B
- 8.8×
- Dividend yield
- 0.0%
- ROE
- −5.9%
- Net margin
- −102.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−58.2% from the high
₩84,300Today: ₩86,600 – ₩100,800₩217,000
Returns
- 1W−7.2%
- 1M−11.8%
- 3M−15.3%
- 6M−51.1%
- YTD−35.5%
- 1Y−9.1%
- Volume today
- 260,316
- 1.1× the 20-day average
- Traded today
- ₩24B
- Listed shares
- 22,874,858
- EPS (12 months)
- −₩613
- Earnings yield −0.7%
AI research · InitiationOliX Pharmaceuticals: Persistent Losses and a High Sales Multiple Behind a ₩2.1T Market ValueThe filed data shows a company with a strong cash position relative to its debt but with deep operating losses, uneven revenue and continued cash burn.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−5.7% on Oct 27, 2026.
- • Foreign investors bought a net ₩1.7B that day
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumWeak-11.4% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 27: buy ₩743M at the close (3.1% of 20-day average trading value)
On its 33 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 7.4% of trading value and pointed the same way 26 of 33 times.
- 2× KODEX KOSDAQ150 Leverage ₩606M
- 2× TIGER KOSDAQ150 Leverage ₩72M
- -1× KODEX KOSDAQ150 Futures Inverse ₩42M
- 2× RISE KOSDAQ150 Futures Leverage ₩13M
- 2× KIWOOM KOSDAQ150 Futures Leverage ₩3.2M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.8%
- KODEX KOSDAQ150 Leverage2×0.8%
- TIGER KOSDAQ1500.8%
- RISE KOSDAQ1500.8%
- TIGER KOSDAQ150 Leverage2×0.8%
- ACE KOSDAQ 1500.8%
- KIWOOM KOSDAQ1500.8%
- SOL KOSDAQ1500.8%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 90,600
Basis 0.00% · implied rate 0.0%
Open interest 7,877 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
OliX Pharmaceuticals stock overview
OliX Pharmaceuticals (올릭스, KRX: 226950) is listed on KOSDAQ, in the Biotech & Pharma sector. Oligonucleotide drug developer built on RNA interference (RNAi) platform technology, including self-delivering asymmetric siRNA (cp-asiRNA), aimed at treating diseases that existing drugs struggle to address. Its shares closed at ₩90,600 on Oct 27, 2026, down 5.72% on the day, giving it a market value of ₩2.1T.
Key facts
- Market cap
- ₩2.1T
- Sector
- Biotech & Pharma
- Latest price change
- −5.72%
- As of
- Oct 27, 2026
- Main business
- Oligonucleotide drug developer built on RNA interference (RNAi) platform technology, including self-delivering asymmetric siRNA (cp-asiRNA), aimed at treating diseases that existing drugs struggle to address.
Quick answers about OliX Pharmaceuticals
- What does OliX Pharmaceuticals do?
- Oligonucleotide drug developer built on RNA interference (RNAi) platform technology, including self-delivering asymmetric siRNA (cp-asiRNA), aimed at treating diseases that existing drugs struggle to address. It develops drug candidates in areas including liver diseases such as MASH and obesity using its GalNAc delivery platform, and also works on topical treatments for skin and eye conditions, and hair loss. Its business model centers on out-licensing its RNAi platform technology and drug candidates to pharmaceutical companies in Korea and abroad, earning technology transfer revenue.
- What is the market cap of OliX Pharmaceuticals?
- The market capitalisation of OliX Pharmaceuticals was ₩2.1T at the close on Oct 27, 2026.
- Who are the largest shareholders of OliX Pharmaceuticals?
- According to the latest official filings, the largest reported holders are Lee Dong-gi (16.93%, as of Jun 1, 2026); National Pension Service (5.04%, as of Apr 1, 2026); Mirae Asset Global Investors (4.47%, as of Sep 1, 2026).
- When is the next earnings report from OliX Pharmaceuticals?
- Korean companies rarely announce results dates in advance. Based on when OliX Pharmaceuticals filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own OliX Pharmaceuticals?
- Yes. The National Pension Service held 5.04% of OliX Pharmaceuticals shares as of Apr 1, 2026.
Company profile
Oligonucleotide drug developer built on RNA interference (RNAi) platform technology, including self-delivering asymmetric siRNA (cp-asiRNA), aimed at treating diseases that existing drugs struggle to address. It develops drug candidates in areas including liver diseases such as MASH and obesity using its GalNAc delivery platform, and also works on topical treatments for skin and eye conditions, and hair loss. Its business model centers on out-licensing its RNAi platform technology and drug candidates to pharmaceutical companies in Korea and abroad, earning technology transfer revenue. Its partners include Jiangsu Hansoh Pharmaceuticals in China and Eli Lilly in the United States.
Written by AI from the company's latest annual report.
- Korean name
- 올릭스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 이동기
- Founded
- Feb 2010
- Listed
- Jul 2018
- Listed shares
- 22,874,858
- Fiscal year ends
- Month 12
- Website
- www.olixpharma.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
[Today's IR] Hyundai Rotem, Allixpharma, Canaphytetherapeutics and Others
Predicted impact: Low
Olix Plunges 14% and Lockit Healthcare Hits 52-Week Low as Clinical Trial Application Rejected [Bio Market Briefing]
Predicted impact: Medium· Actual: −10.0% vs sector, volume 0.6× normal (5 trading days)
Clinical trial application rejection at a different company; Rokit impact unclear, only a 52-week low noted.
Recent filings
See all- Investor relations (IR) eventOct 14, 2026
- Major management matter relevant to investorsOct 12, 2026
- Amended: Major management matter relevant to investorsOct 8, 2026
- Investor relations (IR) eventOct 6, 2026
- Amended: Major management matter relevant to investorsSep 30, 2026
Titles in Korean until English translations are added.
Also known as: OliX Pharmaceuticals / 올릭스 / 226950 / KRX:226950
Source: KRX statistical information